Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3119 participants.

Also called NCT01113372

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose supportive care
Phase
Phase 4
Enrolled
  • 3,119 participants (enrolled count) (from the registry)
Sponsor
  • Medtronic Registry lists this organization as a collaborator
Registry
  • NCT NCT01113372
Other papers using this trial's data
  • Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA, 2013-12-18 DOI, PubMed 24177257

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01113372. Randomized; single masking; primary purpose supportive care. Start 2010-04 (registry gives no type); primary completion 2013-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial
Acronym
OPTIMIZE
Intervention (Drug)
Clopidogrel
Lead sponsor
Cardiovascular Research Center, Brazil (class: other)
Collaborator
Medtronic (class: industry)

Record details

Record id
cardio:ct-nct01113372
Content hash
a46fdf7b4f261c2e1b23eeb0a13593402153ca60f5d7e08515a3e947396d68a4